Home > News > Ghrelin – Physiological Functions and Regulation
Obesity
Read Time: 13 mins

Ghrelin – Physiological Functions and Regulation

Published Online: August 19th 2015 European Endocrinology, 2015;11(2):90–5 DOI: http://doi.org/10.17925/EE.2015.11.02.90
Authors: Mona Mohamed Ibrahim Abdalla
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Ghrelin is an orexigenic peptide predominantly secreted from the stomach and stimulates appetite and growth hormone (GH) release. Studies have provided evidence that ghrelin exercises a wide range of functions, including regulation of food intake and energy metabolism, modulation of cardiovascular function, stimulation of osteoblast proliferation and bone formation and stimulation of neurogenesis and myogenesis. In the gastrointestinal system, ghrelin affects multiple functions, including secretion of gastric acid, gastric motility and pancreatic protein output. Most of these functions have been attributed to the actions of acylated ghrelin. The balance among its secretion rate, degradation rate and clearance rate determines the circulating level of ghrelin. This review explains what ghrelin is, its physiological functions and the factors that influence its level.

Keywords

Ghrelin, food intake, obesity, lipolysis, ghrelin receptors, regulation

Article:

Ghrelin is a 28-amino-acid peptide predominantly secreted in the stomach and stimulates appetite and growth hormone (GH) release. The name ghrelin is based on ‘ghre’ a word root in Proto-Indo-European languages meaning ‘grow’ in reference to its ability to stimulate GH release. In 1976, Bowers and co-workers discovered opioid peptide derivatives that did not exhibit any opioid activity, but had weak GH-releasing activity, and were referred to as GH secretagogues (GHSs).1 GHSs act on the pituitary and hypothalamus to release GH, not through the GH-releasing hormone receptor (GHRH-R) but through an orphan receptor, the GHS-R.2 Synthetic GHSs and the GHS-R indicated that an unknown endogenous ligand for GHS-R should exist. In December 1999, Kojima et al. were the first to purify and identify ghrelin from rat stomach as the endogenous ligand for the GHS-R.1

Expression and Synthesis of Ghrelin

Approximately 60–70 % of circulating ghrelin is secreted by the stomach, with most of the remainder originating in the small intestine. Low-level ghrelin expression also occurs in several tissues outside the gut, including hypothalamus (arcuate nucleus and paraventricular nucleus), pituitary, lung, adrenal cortex, kidney, bone, testis, placenta and pancreatic islet cells.3 In the stomach, the ghrelin-containing cells are more abundant in the fundus than in the pylorus originally termed X/A-like cells. These X/A-like cells account for approximately 20 % of the endocrine cell population in adult oxyntic glands. However, the number of X/A-like cells in the foetal stomach is very low and increases after birth. As a result, the ghrelin concentration of foetal stomach is also very low and gradually increases after birth until 5 weeks of age.4

The human preproghrelin gene is located on chromosome 3p25-26 and consists of five exons with four introns. Spliced ghrelin messenger (mRNA) is translated to a 117-amino acid preproghrelin precursor, which is subsequently cleaved to yield ghrelin. In addition, obestatin, a 23-amino acid peptide is a putative proteolytic fragment of the preproghrelin precursor purified from rat stomach extracts. In contrast to the appetitestimulating effects of ghrelin, treatment of rats with obestatin suppressed food intake, inhibited jejunal contraction and decreased bodyweight gain.5 However the appetite suppressing effect of obestatin failed to be demonstrated in.6 The amino acid sequences of mammalian ghrelin are well conserved, particularly the 10 amino acids in their NH2 termini, which are identical. This structural conservation and the universal requirement for acyl-modification of the third residue indicate that this NH2-terminal region is of central importance to the activity of the peptide. Rat and human ghrelin differ in only two amino acid residues.2

Plasma Level of Ghrelin

The measurement of ghrelin levels is affected by blood collection and storage conditions.7 To ensure ghrelin stability, it is strongly recommended to collect blood samples with EDTA-aprotinin (or other proteases inhibitors) under cooled conditions and proceed to the sample acidification and dilution prior to ghrelin measurement.8 Recently, an addition of esterase inhibitor to the ghrelin measurement guidelines was found to enhance ghrelin stabilisation.9

The plasma ghrelin-like immunoreactivity concentration in normal humans measured by a specific radioimmunoassay (RIA) was 166.0 ± 10.1 fmol/ml. Serum ghrelin concentrations increase with age with no sex difference and vary widely throughout the day, with higher values during sleep.10 Other studies have shown differences in gastric ghrelin cells and ghrelin levels in serum between women and men, indicating that secretion of the hormone can be under control of sex hormones or other unknown factors.11 Novel methods permit accurate means to detect the different forms of circulating ghrelin and determine how various manipulations influence the levels of these different forms.12 The sandwich enzyme-linked immunosorbent assays (ELISAs) were found to be more sensitive in measuring ghrelin levels and are also available for both forms of ghrelin.13

The two major different circulating forms of ghrelin that exist in rats and man are the acylated (or n-octanoylated, AG) and unacylated (or des-octanoylated or des-acylated, UAG). AG has a unique feature that is a post-translational esterification of a fatty (n-octanoic or, to a lesser extent, n-decanoic) acid on serine residue at position 3. Ghrelin O-acyltransferase (GOAT) is a membrane-bound enzyme responsible for this octanoylation by attaching an 8-carbon medium-chain fatty acid (MCFA) (octanoate) to serine 3 of ghrelin. This acylation is necessary for the activity of ghrelin. Animal data suggest that MCFAs provide substrate for GOAT and an increase in nutritional octanoate increases acyl-ghrelin.14

Ghrelin acylation is necessary for its actions via GHS-R1a. Normally, AG accounts for less than 10 % of the total ghrelin in the circulation. The majority of circulating ghrelin is UAG.15 UAG was first considered an inactive form of ghrelin, although accumulating evidence indicates that UAG can modulate metabolic activities of the ghrelin system either independently or in opposition to those of AG.16

Ghrelin Receptors and their Distribution

The GHSR mRNA is expressed as two splice variants encoding the cognate receptor GHS-R1a and the apparently non-functional receptor GHS-R1b. Unlike GHS-R1a, GHS-R1b is not activated by ghrelin or synthetic GHS and it is unclear whether it is a functional receptor.17 It has been shown that GHS-R1b is likely not correctly transported and accumulates in the nucleus, and is thus very likely inactive.18 GHS-R1a consists of 366 amino acids. It is a seven transmembrane G-protein-coupled receptor with a high degree of constitutive, ligand-independent signalling activity as it signals with approximately 50 % of its maximal signalling, depending on the signal transduction pathway, without the presence of any hormone. The constitutive activity of GHSR is based on in vitro overexpression experiments. The level of expression is so low in vivo that constitutive activity is unlikely to be of consequence.19 This constitutive activity of the ghrelin receptor is of physiological importance.20

GHS-R1b mRNA is as widely expressed as ghrelin, whereas GHS-R1a gene expression is concentrated in the hypothalamus–pituitary unit, although it is also distributed in other central and peripheral tissues. Centrally, in areas of the central nervous system (CNS) that affect biological rhythms, mood, cognition, memory and learning, such as the hippocampus, pars compacta of the substantia nigra, ventral tegmental area (VTA), dorsal and medial raphe nuclei, Edinger–Westphal nucleus and pyriform cortex.21 However, published descriptions of the distributions of ghrelin-like immunoreactivity in the CNS are inconsistent.22

Peripherally, the GHS-R1a gene is expressed in the stomach, intestine, pancreas, thyroid, gonads, adrenal, kidney, heart and vasculature, as well as several endocrine tumours and cell lines, and have been found to express GHS-R1a with negligible binding found in the parathyroid, pancreas, placenta, mammary gland, prostate, salivary gland, stomach, colon and spleen.23 This wide distribution of GHS-R1a indicates that the ghrelin and synthetic GHS possess broader functions beyond the control of GH release and food intake.24

Physiological Functions of Ghrelin

Ghrelin exercises a wide range of functions including, regulation of food intake and energy metabolism, stimulation of gastric acid secretion, motility and pancreatic protein output,1 modulation of cardiovascular function (reviewed in reference 24), stimulation of osteoblast proliferation and bone formation,25 stimulation of neurogenesis26 and myogenesis,27 learning and memory,28 thymopoiesis,29 sleep/wake rhythm,30 ageing31 and a neuroprotective role in neurodegenerative diseases (e.g., Parkinson’s disease).32

Growth Hormone-releasing Effect

The GH-releasing effect of the ghrelin occurs through direct effect of ghrelin on pituitary somatotroph cells,33 synergistic effect with GHRH34 and through stimulation of vagal afferents.35 In high doses, ghrelin may also stimulate prolactin, corticotropin and cortisol secretion in humans.36

Orexigenic Effect (Appetite-stimulating Effect)

Ghrelin is the only known orexigenic gut peptide. The pre-prandial elevation of ghrelin levels and its fall after meals led to the notion that ghrelin was a ‘hunger’ hormone responsible for meal initiation. Ghrelin is involved in short-term regulation of food intake and long-term regulation of bodyweight through decreasing fat utilisation.37 The effect of ghrelin on feeding is mediated through the GHS-R1a, as indicated by the lack of its orexigenic effect in GHS-R knocked out mice.38 GHS-R1a is highly expressed in hypothalamic cell populations that regulate feeding and bodyweight homeostasis.39

In the arcuate nucleus (ARC), the ghrelin-containing neurons send efferent fibres onto neuropeptide Y(NPY) and agouti related peptide (AgRP)-expressing neurons to stimulate the release of these orexigenic peptides. Ghrelin has also been reported to inhibit the firing of proopiomelanocortin (POMC) neurons by increasing the frequency of spontaneous synaptic γ-aminobutyric acid (GABA) release onto them in a pattern representing a functional antagonism to leptin, without affecting POMC mRNA expression. Confirming that ghrelin’s orexigenic effect is mediated by specific modulation of AgRP/NPY neurons in the ARC, no change was demonstrated in the mRNA levels of the other feeding– promoting neuropeptides such as melanocyte stimulating hormone (MCH) and prepro-orexin (OX). Recent data indicate that the orexigenic effect of ghrelin is mediated by its modulation of hypothalamic adenosine monophosphate (AMP)-activated protein kinase (AMPK) enzyme activity.40

The detection of ghrelin receptors on vagal afferent neurons in the rat suggests that ghrelin signals from the stomach are transmitted to the brain via the vagus nerve.35 However, whether integrity of the vagus nerve is crucial for effects of ghrelin and whether vagotomy prevents its orexigenic effect in animal models and humans is not universally accepted, as cutting vagal afferents were not necessary for the orixigenic effect of the peripherally injected ghrelin in rats,41 and gastrectomy in humans accompanied by vagatomy did not prevent the orexigenic effects of ghrelin treatment, indicating an intact vagus is not required for its orexigenic effects.42

Ghrelin and Glucose Homeostasis

Since 2000, numerous studies have suggested that ghrelin has an important role in regulating β-cell function of the pancreas and glucose homeostasis. Indeed, the weight of evidence could support even a more physiologically important function in the control of glucose homeostasis than appetite regulation.43 The available data suggest a negative association between systemic ghrelin and insulin levels.44 There is controversy in the role of ghrelin in insulin secretion as ghrelin has been shown to inhibit insulin secretion in some experiments.45–47 and stimulate insulin release in others.48,49 These discrepancies may be due to differences in species and/or experimental design. Plasma ghrelin and insulin levels are affected by blood glucose level, as high glucose suppresses ghrelin secretion and stimulates insulin secretion. Ghrelin also inhibits insulin effects on glycogen synthesis and gluconeogenesis in vitro. Ghrelin may also inhibit secretion of the insulin-sensitising protein adiponectin from adipocytes and stimulate secretion of the counter-regulatory hormones, including GH, cortisol, epinephrine and (possibly) glucagon. More studies are needed to clarify the precise physiological role of ghrelin on the regulation of glucose homeostasis.50 Pharmacological inhibition of GOAT51 and ghrelin ablation in ob/ob mice52 improves glucose tolerance and insulin sensitivity.

Ghrelin and Lipid Metabolism

Ghrelin is now thought to play a significant role in the regulation of lipid storage in white adipose tissue (WAT). Although acute ghrelin exposure also induces GH secretion, the net effect of prolonged ghrelin exposure is increased fat mass. Ghrelin has been reported to enhance adipogenesis, augment fat storage enzyme activity, elevate triglyceride content and reduce fat utilisation/lipolysis.53–55

Evidence has demonstrated that administration of peripheral ghrelin increases WAT mass in selective abdominal depots (retroperitoneal and inguinal) via a decrease in lipid export rather than a decrease in lipolysis per se. Thus, during periods of energy insufficiency, ghrelin may prevent lipid loss from responsive adipocytes thereby permitting depot-specific utilisation of energy reserves. It was also found that ghrelin-induced lipid accumulation is not specific to WAT, as exogenous ghrelin markedly increased the number of lipid droplets in the livers of treated rats and mice, an effect mediated by direct activation of its receptor on hepatocytes. Ghrelin receptor antagonism or gene deletion significantly decreased obesity-associated hepatic steatosis by suppression of de novo lipogenesis.55,56

Is Ghrelin Essential for Life?

Total gastrectomy was shown to decrease the plasma concentrations of ghrelin to approximately 30–50 % of those of pregastrectomy when measured at 30 minutes after the operation. This concentration gradually increased to about 70 % of the level before the operation. These results indicate that decreased ghrelin production after gastrectomy is subject to compensatory production possibly by the intestines and pancreas.57 The increased ghrelin levels after gastric bypass surgery were associated with altered ghrelin cell responsiveness to two major physiological modulators of ghrelin secretion – glucose and norepinephrine. This provides new insights into the regulation of ghrelin secretion and its relation to circulating ghrelin within the contexts of obesity and weight loss.58

Although ghrelin is not essential for food intake in mice, it is required for certain food reward behaviours that occur in the setting of chronic calorie restriction. Ghrelin is also essential in mice to prevent hypoglycaemia and death when the animals are subjected to severe calorie restriction. The latter function of ghrelin became apparent in studies of genetically engineered mice that lack the gene encoding GOAT enzyme59 and ghrelin-deficient mice.60

Regulation of Ghrelin Secretion

The circulating level of ghrelin is determined by the balance among its secretion, degradation and clearance rates. Plasma esterases have been reported to des-acylate acyl ghrelin, whereas plasma proteases account for the degradation of circulating ghrelin. Clearance of circulating ghrelin includes being captured by its receptor and excreted in urine. Besides, acyl ghrelin can transport across the blood–brain barrier bidirectionally through specific transport system in humans.61 Ghrelin secretion has been found to be modified under different conditions such as fasting, pathological conditions and surgery.62

In contrast to other gut hormones, plasma ghrelin levels increase in response to fasting and decrease on refeeding.63 Furthermore, plasma ghrelin levels are reduced by chronic intake of high-calorie diets and obesity in humans. In rodents, prolonged exposure to high-fat (HF) diets will result in a positive energy balance, obesity and a reduction of stomach production and secretion of ghrelin.63–65 However, an increase in the number of ghrelin secreting cells in response to the HF diet has been shown in a recent study.66 The extent to which the increased adiposity exerts an inhibitory influence on stomach ghrelin production and secretion is not well known.67 The mechanism of pre-prandial increase in ghrelin levels is evidenced to be noradrenergic mediated,68 and the post-prandial decrease by increase in glucose and insulin. However, the regulating role of insulin on post-prandial ghrelin suppression is rather additive.68,69

Low systemic ghrelin levels have been reported in obesity, untreated hyperthyroidism,70 in male hypogonadism,71 in polycystic ovary syndrome72 and in the presence of Helicobacter pylori-induced gastritis.73 Plasma ghrelin levels are high in anorexia nervosa patients and return to control levels after weight gain by renutrition, in lean people, Prader-Willi syndrome and after eradication of H. pylori.73

Primary cell cultures of dispersed gastric mucosal cells from adult mice and new-born rats have been developed to investigate the mechanisms regulating ghrelin synthesis and secretion.74,75 Ghrelinsecreting immortalised cell lines developed from ghrelinomas in the stomachs and pancreatic islets of transgenic mice expressing SV40 large T-antigen under the control of preproghrelin promoter are now available models.68,76 Using these models, modulation of ghrelin release by different factors, such as peptide hormones, monoaminergic neurotransmitters, glucose, fatty acids, second messengers, potential downstream effector enzymes and channels, has now been investigated. Insulin, glucagon, oxytocin, somatostatin, dopamine, glucose and longchain fatty acids have all been shown to regulate ghrelin secretion through their direct interaction with ghrelin cells.62,68,74–76

Nutrients and Ghrelin Level

Isocaloric intestinal infusions of either glucose or amino acids have been found to suppress ghrelin levels more rapidly and effectively than lipid infusions. Theoretically, weak suppression of an orexigenic hormone by ingested lipids could be one of the mechanisms underlying HF dietinduced weight gain. The rate of nutrient absorption and the increase in osmolarity within the intestinal lumen may partly explain the difference in ghrelin suppression by different types of food. Glucose and amino acids, which are quickly absorbed from the gut, suppressed ghrelin rapidly and deeply. By contrast, lipids that require intestinal digestion before absorption lead to weak suppression of ghrelin levels.77

The underlying mechanisms that mediate suppression of systemic ghrelin secretion by food are not well known. This may be due to direct nutrient sensing in ghrelin-producing cells and the gut peptides released in response to food intake as insulin, glucagon-like-peptide 1 (GLP-1), peptide YY (PYY) and cholecystokinin (CCK) as they increase rapidly after food intake and circulating ghrelin levels begin to fall simultaneously (reviewed in reference 78).

Hormones Regulating Ghrelin Expression and Secretion

Insulin

Several observations in humans and rats indicate that insulin may inhibit ghrelin secretion and decrease the total serum ghrelin level. GLP-1 has been reported to alleviate the pre-prandial rise of ghrelin in human beings because it is a potent stimulator for insulin secretion.79 This inhibitory effect of insulin on ghrelin level may underlie the suppression of glucose on ghrelin and the inverse relationship between bodyweight and ghrelin level. It may also explain the low ghrelin level in patients of type 2 diabetes mellitus.80 The rise in ghrelin after insulin administration81 was explained by severe hypoglycaemia induced by rapid injection of high dose of insulin.82 Thus, the influence of insulin and glucose on ghrelin secretion is possibly contradictory and independent. Although some studies found a negative correlation between ghrelin level and insulin resistance,83,84 there is plenty of data suggesting the reverse, as ablation of ghrelin and ghrelin receptors improves insulin sensitivity.51,84,85 and ghrelin infusion in humans impairs glucose tolerance in hyperinsulinaemic euglycaemic clamp studies.86

Glucagon

Glucagon may contribute to the pre-prandial surge of ghrelin as evidenced by the 1) glucagon receptor present in endocrine cells in gastric mucosa, 2) glucagon concentration increases during fasting, 3) plasma acyl ghrelin concentration rises transiently while des-acyl ghrelin increases persistently after administration of glucagon in rats, 4) ghrelin released from the rat stomach is augmented by glucagon perfusion, and 5) glucagon may directly stimulate the gene transcription of ghrelin. Ghrelin has recently been shown to be directly regulated by glucagon.87

Leptin (Ghrelin–Leptin Tango)

Although some studies88 found no correlation between ghrelin and leptin levels in obese children and adolescents, other studies suggest that there is a complex interaction between leptin and ghrelin.89 Immunoneutralisation of circulating plasma ghrelin with specific immunoglobulin (Ig)-G anti-ghrelin antibodies caused a marked increase in plasma leptin and decrease in food intake. By contrast, exogenous leptin, at the dose that raises plasma leptin to the level occurring postprandially, markedly reduced plasma levels of ghrelin and attenuated food intake. These effects are reversed by the administration of specific IgG anti-leptin antibodies.90 It has been shown that leptin inhibits both the secretion of gastric ghrelin and the stimulation of feeding by ghrelin. This cross-talk between leptin and ghrelin has been termed as the ‘ghrelin–leptin tango’ in bodyweight regulation. This hypothesis clarifies that the weight-reducing effects of leptin are mediated not only by its direct central action on the hypothalamus but also through its peripheral inhibitory effect on the release and action of ghrelin.91

Growth Hormone/Insulin-like Growth Factor-1 Axis and Somatostatin

GH exerts a negative feedback action on ghrelin production and secretion so GH therapy in GH deficient patients significantly decreases the serum acyl ghrelin concentration.92 As insulin-like growth factor-1 (IGF-1) functions to inhibit GH secretion, it may induce ghrelin secretion either directly or indirectly.93 Somatostatin possibly inhibits ghrelin synthesis directly. This inhibitory effect of somatostatin on ghrelin may be considered as a negative feedback modulation as ghrelin increases the level of somatostatin in plasma.94 Cortisol and fatty acids also exert a negative feedback on ghrelin secretion. The increase of ghrelin at and before midnight may be explained by low cortisol at that time.95

Oestrogen

There is controversy in the effect of oestrogen on ghrelin levels. Many studies reported that oestrogen up-regulates the ghrelin level.96 However, oestrogen-replacement therapy in post-menopausal women increases serum total and acyl ghrelin secretion only to an insignificant extent, or even decreases serum total ghrelin level.97 It was also found that plasma acyl ghrelin concentration, ghrelin expressing cells and ghrelin mRNA levels in the stomach increase transiently after ovariectomy in female rats.98 In addition, ghrelin and oestrogen receptor immunoreactivities were demonstrated in the same cells, suggesting that oestrogen may have a direct effect on ghrelin expression.96

Autonomic Nervous System

The autonomic nervous system plays an important role in the regulation of ghrelin. Excitation of the vagus nerve can stimulate ghrelin secretion. In rats and humans, ghrelin levels rise after administration of muscarinic agonists and fall after administration of muscarinic antagonists.99,100 This stimulatory effect is probably a direct effect on ghrelin-producing cells that are governed by the enteric nervous system in stomach mucosa.61 Sympathetic nervous system is also involved in the regulation of ghrelin, as plasma acyl ghrelin concentration is induced by an α-adrenergic antagonist and a β-adrenergic agonist. The adrenergic agents act directly on β1 receptors in ghrelin-secreting cells.68 Vagotomy has been reported to inhibit the secretion of gastric ghrelin acutely, but activates its secretion in the long term, suggesting that ghrelin secretion is modulated by the balance between cholinergic and adrenergic tones that control the enteric nervous system.101,102

Clinical Applications of Ghrelin and Ghrelin Antagonist

In the past decade, clinical applications of ghrelin have been attempted for various pathologies, based on its anabolic function, including applications for patients with cachexia, sarcopenia (muscle wasting due to ageing),103 myopenia (muscle wasting due to chronic illness)103 and frailty states.104,105 Among the first applications of ghrelin in human chronic illness were studies in congestive heart failure (CHF)106 and chronic obstructive pulmonary disease (COPD).107,108

In the field of surgery, ghrelin comprehensively improves the patients’ general conditions and quality of life via its pleiotropic physiological functions. This characteristic is unique and different from the existing drugs. Therefore, ghrelin may be an indispensable supplement to prevent surgical stress and post-operative sequelae.109

Several synthetic ghrelin mimetics are being pursued in clinical trials for diverse indications.62 Three compounds are currently in development. Macimorelin is in clinical trials for the diagnosis of GH deficiency.110 A second compound, anamorelin, is in clinical trials for the treatment of cancer cachexia.111 A third compound, relamorelin (also known as RM-131) is currently in phase II clinical trials and is being developed for treatment of diabetic gastroparesis and other gastrointestinal (GI) disorders.112

The orexigenic and lipogenic effect of ghrelin provide a potential use of ghrelin antagonists or reverse agonists in the treatment of obesity.113 However, studies in this area show conflicting results as ghrelin antagonist reduced bodyweight and food intake in some studies,114,115 while it increased weight gain and food intake in another studies.116,117 [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P was identified as an inverse agonist on GHS-R1a,118 and several classes of ghrelin receptor antagonists have been developed (reviewed in reference 119).

Conclusion

Ghrelin exerts many physiological roles and is regulated by several factors. Understanding the mechanisms of ghrelin regulation by modifying its secretion, acylation and degradation will provide a better therapeutic benefit of ghrelin, ghrelin mimetics, inverse agonists and ghrelin antagonists.

Article Information:
Disclosure

Mona Mohamed Ibrahim Abdalla has no conflicts of interest to declare

Correspondence

Mona Mohamed Ibrahim Abdalla, Jalan Elmu, Off Jalan University, 59100, Kuala Lumpur, Malaysia. E: monaalbetar@yahoo.com

Access

This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation
and reproduction provided the original author(s) and source are given appropriate credit.

Received

2015-06-11T00:00:00

References

1. Kojima M, Hosoda H, Date Y, et al., Ghrelin is a growthhormone- releasing acylated peptide from stomach, Nature, 1999;402:656–60.
2. Kojima M, Kangawa K, Ghrelin: structure and function, Physiol Rev, 2005; 85:495–522.
3. Banerjee RR, Rangwala SM, Shapiro JS, et al., Regulation of fasted blood glucose by resistin. Science, 2004;303:1195–8.
4. Konturek PC, Brzozowski T, Pajdo R, et al., Ghrelin-a new gastroprotective factor in gastric mucosa, J Physiol Pharmacol, 2004;55:325–36.
5. Hassouna R, Zizzari P, Tolle V, The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake, J Neuroendocrinol, 2010;22:7793–804.
6. Mora M, Granada ML, Roca M, et al., Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women, Clin Endocrinol (Oxf), 2013;78:882–90.
7. Tvarijonaviciute A, Martínez-Subiela S, Ceron JJ, Influence of different storage conditions and anticoagulants on the measurement of total and acylated ghrelin in dogs: a preliminary study, Vet Rec, 2013;172:289.
8. Hosoda H, Kangawa K, Standard sample collections for blood ghrelin measurements, Methods Enzymol, 2012;514:113–26.
9. Delhanty PJ, Huisman M, Julien M, et al., The acylated (AG) to unacylated (UAG) ghrelin ratio in esterase inhibitor-treated blood is higher than previously described, Clin Endocrinol (Oxf), 2015;82(1):142–6.
10. Drazen DL, Vahl TP, D’Alessio DA, et al., Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status, Endocrinol, 2006;147:23–30.
11. Kasacka I, Arciszewski M, Janiuk I, Lebkowski W, Comparative evaluation of gastric ghrelin cells and levels of hormone in the serum of healthy women and men, J Biol Regul Homeost Agents, 2013;27:69–78.
12. Prudom C, Liu J, Patrie J, et al., Comparison of competitive radioimmunoassays and two-site sandwich assays for the measurement and interpretation of plasma ghrelin levels, J Clin Endocrinol Metab, 2010;95:2351–8.
13. Akamizu T, Shinomiya T, Irako T, et al., Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay, J Clin Endocrinol Metab, 2005;90:6–9.
14. Nass R, Nikolayev A, Liu J, et al., The level of circulating octanoate does not predict ghrelin O-acyl transferase (GOAT)- mediated acylation of ghrelin during fasting, J Clin Endocrinol Metab, 2015;100:E110–3.
15. Sangiao-Alvarellos S, Cordido F, Effect of ghrelin on glucoseinsulin homeostasis: therapeutic implications, Int J Pept, 2010;2010:pii:234709.
16. Delhanty PJ, Sun Y, Visser JA, et al., Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice, PLoS One, 2010;5:e11749.
17. Chan CB, Cheng CH, Identification and functional characterization of two alternatively spliced growth hormone secretagogue receptor transcripts from the pituitary of black seabream Acanthopagrus schlegeli, Mol Cell Endocrinol, 2004;214:81–95.
18. Smith RG, Jiang H, Sun Y, Developments in ghrelin biology and potential clinical relevance, Trends Endocrinol Metab, 2005;16:436–42.
19. Kern A, Albarran-Zeckler R, Walsh HE, Smith RG, Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism, Neuron, 2012;73:317–32.
20. Holst B, Mokrosinski J, Lang M, et al., Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism, J Biol Chem, 2007;282:15799–811.
21. Van der Lely AJ, Unacylated ghrelin rapidly modulates lipogenic and insulin signaling pathway gene expression in metabolically active tissues of GHSR deleted mice, PloS One, 2010;5:e11749.
22. Furness JB, Hunne B, Matsuda N, et al., Investigation of the presence of ghrelin in the central nervous system of the rat and mouse, Neuroscience, 2011;193:1–9.
23. Venables G, Hunne B, Bron R, et al., Ghrelin receptors are expressed by distal tubules of the mouse kidney, Cell Tissue Res, 2011;346:135.
24. Zhang G, Yin X, Qi Y, et al., Ghrelin and cardiovascular diseases, Curr Cardiol Rev, 2010;6:62–70.
25. Fukushima N, Hanada R, Teranishi H, et al., Ghrelin directly regulates bone formation, J Bone Miner Res, 2005;20:790–8.
26. Li E, Chung H, Kim Y, et al., Ghrelin directly stimulates adult hippocampal neurogenesis: implications for learning and memory, Endocr J, 2013;60:781–9.
27. Zhang W, Zhao L, Mulholland MW, Ghrelin stimulates myocyte development, Cell Physiol Biochem, 2007;20:659–64.
28. Diano S, Farr SA, Benoit SC, et al., Ghrelin controls hippocampal spine synapse density and memory performance, Nat Neurosci, 2006;9:381–8.
29. Dixit VD, Yang H, Sun Y, et al., Ghrelin promotes thymopoiesis during aging, J Clin Invest, 2007;117:2778–90.
30. Szentirmai E, Kapás L, Sun Y, et al., Spontaneous sleep and homeostatic sleep regulation in ghrelin knockout mice, Am J Physiol Regul Integr Comp Physiol, 2007;293:R510–7.
31. Andrews ZB, Erion D, Beiler R, et al., Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism, J Neurosci, 2009;29:14057–65.
32. Moon M, Kim HG, Hwang L, et al., Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation, Neurotox Res, 2009;15:332–47.
33. Picha ME, Strom CN, Riley LG, et al., Plasma ghrelin and growth hormone regulation in response to metabolic state in hybrid striped bass: effects of feeding, ghrelin and insulin-like growth factor-I on in vivo and in vitro GH secretion, Gen Comp Endocrinol, 2009;161:365–72.
34. Leal-Cerro A, Garcia E, Astorga R, et al., Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency, Eur J Endocrinol, 1995;132:712–5.
35. Date Y, Ghrelin and the vagus nerve, Methods Enzymol, 2012;514:261–9.
36. Coiro V, Volpi R, Stella A et al., Oxytocin does not modify GH, ACTH, cortisol and prolactin responses to Ghrelin in normal men, Neuropeptides, 2011;45:139–42.
37. Castañeda TR, Tong J, Datta R, et al., Ghrelin in the regulation of body weight and metabolism, Front Neuroendocrinol, 2010;31:44–60.
38. Sun Y, Wang P, Zheng H, Smith RG, Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor, Proc Natl Acad Sci U S A, 2004;101:4679–84.
39. Cowley MA, Smith RG, Diano S, et al., The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis, Neuron, 2003;37:649–61.
40. Kola B, Farkas I, Christ-Crain M, et al., The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system, PLoS One, 2008;3:e1797.
41. Arnold M, Mura A, Langhans W, Geary N, Gut vagal afferents are not necessary for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat, J Neurosci, 2006;26:11052–60.
42. Adachi S, Takiguchi S, Okada K, et al., Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study, Gastroenterology, 2010;138:1312–20.
43. Sangiao-Alvarellos S, Cordido F, Effect of ghrelin on glucoseinsulin homeostasis: therapeutic implications. Int J Pept, 2010;234709.
44. Chabot F, Caron A, Laplante M, St-Pierre DH, Interrelationships between ghrelin, insulin and glucose homeostasis: Physiological relevance, World J Diabetes, 2014;5:328–41.
45. Dezaki K, Sone H, Yada T, Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis, Pharmacol Ther, 2008;118:239–49.
46. Tong J, Prigeon RL, Davis HW, et al., Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans, Diabetes, 2010;59:2145–51.
47. Wang Y, Nishi M, Doi A, et al., Ghrelin inhibits insulin secretion through the AMPK-UCP2 pathway in beta cells, FEBS Lett, 2010;584:1503–8.
48. Adeghate E, Ponery AS, Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats, J Neuroendocrinol, 2002;14:555–60.
49. Takahashi H, Kurose Y, Kobayashi S, et al., Ghrelin enhances glucose-induced insulin secretion in scheduled meal-fed sheep, J Endocrinol, 2006;189:67–75.
50. Barnett BP, Hwang Y, Taylor MS, et al., Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor, Science, 2010;330:1689–92.
51. Sun Y, Asnicar M, Saha PK, et al., Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice, Cell Metab, 2006;3:379–86.
52. Tsubone T, Masaki T, Katsuragi I, et al., Ghrelin regulates adiposity in white adipose tissue and UCP1 mRNA expression in brown adipose tissue in mice, Regul Pept, 2005;130:97–103.
53. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al., Ghrelin action in the brain controls adipocyte metabolism, J Clin Invest, 2006;116:1983–93.
54. Davies JS, Kotokorpi P, Eccles SR, et al., Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention, Mol Endocrinol, 2009;23:914–24.
55. Perez-Tilve D, Heppner K, Kirchner H, et al., Ghrelin-induced adiposity is independent of orexigenic effects, FASEB J, 2011;25:2814–22.
56. Li Z, Xu G, Qin Y, et al., Ghrelin promotes hepatic lipogenesis by activation of mTOR-PPARγ signaling pathway, Proc Natl Acad Sci U S A, 2014;111:13163–8.
57. Leonetti F, Silecchia G, Iacobellis G et al., Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects, J Clin Endocrinol Metab, 2003;88:4227–4231.
58. Uchida A, Zechner JF, Mani BK, et al., Altered ghrelin secretion in mice in response to diet-induced obesity and Roux-en-Y gastric bypass, Mol Metab, 2014;3:717–30.
59. Zhao TJ, Liang G, Li RL, et al., Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorierestricted mice, Proc Natl Acad Sci U S A, 2010;107:7467–72.
60. Li RL, Sherbet DP, Elsbernd BL et al., Profound hypoglycemia in starved, ghrelin-deficient mice is caused by decreased gluconeogenesis and reversed by lactate or fatty acids, J Biol Chem, 2012;287:17942–50.
61. Yin X, Li Y, Xu G, et al., Ghrelin fluctuation, what determines its production? Acta Biochim Biophys Sin (Shanghai), 2009;41:188–97.
62. Müller TD, Nogueiras R, Andermann ML, et al., Ghrelin, Mol Metab, 2015;4:437–60. Review.
63. Cummings DE, Purnell JQ, Frayo RS, et al., A pre-prandial rise in plasma ghrelin levels suggests a role in meal initiation in humans, Diabetes, 2001;50:1714–9.
64. Lee HM, Wang G, Englander EW, et al., Ghrelin, a new gastrointestinal endocrine peptide that stimulates insulin secretion: enteric distribution, ontogeny, influence of endocrine, and dietary manipulations, Endocrinology, 2002;143:185–90.
65. Tschop M, Weyer C, Tataranni PA, et al., Circulating ghrelin levels are decreased in human obesity, Diabetes, 2001;50:707–9.
66. Widmayer P, Goldschmid H, Henkel H, et al., High fat feeding affects the number of GPR120 cells and enteroendocrine cells in the mouse stomach, Front Physiol, 2015;6:53.
67. Qi X, Reed JT, Wang G, et al., Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity, Am J Physiol Regul Integr Comp Physiol, 2008;295:R429–35.
68. Zhao TJ, Sakata I, Li RL, et al., Ghrelin secretion stimulated by {beta} 1-adrenergic receptors in cultured ghrelinoma cells and in fasted mice, Proc Natl Acad Sci U S A, 2010;107:15868–73.
69. Williams DL, Cummings DE, Grill HJ, Kaplan JM, Mealrelated ghrelin suppression requires postgastric feedback, Endocrinology, 2003;144:2765–7.
70. Riis AL, Hansen TK, Møller N, et al., Hyperthyroidism is associated with suppressed circulating ghrelin levels, J Clin Endocrinol Metab, 2003;88:853–7.
71. Pagotto U, Gambineri A, Pelusi C, et al., Testosterone replacement therapy restores normal ghrelin in hypogonadal men, J Clin Endocrinol Metab, 2003;88:4139–43.
72. Pagotto U, Gambineri A, Vicennati V, et al., Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels, J Clin Endocrinol Metab, 2002;87:5625–9.
73. Lee ES, Yoon YS, Park CY, et al., Eradication of Helicobacter pylori increases ghrelin mRNA expression in the gastric mucosa, J Korean Med Sci, 2010;25:265–71.
74. Gagnon J, Anini Y, Insulin and norepinephrine regulate ghrelin secretion from a rat primary stomach cell culture, Endocrinology, 2012;153:3646–56.
75. Sakata I, Park WM, Walker AK, et al., Glucose-mediated control of ghrelin release from primary cultures of gastric mucosal cells, Am J Physiol Endocrinol Metab, 2012;302:E1300–10.
76. Iwakura H, Li Y, Ariyasu H, et al., Establishment of a novel ghrelin-producing cell line, Endocrinology, 2010;151:2940–5.
77. Guo ZF, Ren AJ, Zheng X, et al., Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expressions in rats, Peptides, 2008;29:1247–54.
78. Koliaki C, Kokkinos A, Tentolouris N, Katsilambros N, The effect of ingested macronutrients on post-prandial ghrelin response: a critical review of existing literature data, Int J Pept, 2010;710852.
79. Hagemann D, Holst JJ, Gethmann A, et al., Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion, Regul Pept, 2007;143:64–8.
80. Pöykkö SM, Kellokoski E, Hörkkö S, et al., Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 Diabetes, Diabetes, 2003;52:2546–53.
81. Toshinai K, Mondal MS, Nakazato M, et al., Upregulation of Ghrelin expression in the stomach upon fasting, insulininduced hypoglycemia, and leptin administration, Biochem Biophys Res Commun, 2001;281:1220–5.
82. Flanagan DE, Evans ML, Monsod TP, et al., The influence of insulin on circulating ghrelin, Am J Physiol Endocrinol Metab, 2003;284:E313–6.
83. Purnell JQ, Weigle DS, Breen P, Cummings DE, Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans, J Clin Endocrinol Metab, 2003;88:5747–52.
84. Amini P, Wadden D, Cahill F, et al., Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study, PLoS One, 2012;7:e45657.
85. Qi Y, Longo KA, Giuliana DJ, et al., Characterization of the insulin sensitivity of ghrelin receptor KO mice using glycemic clamps, BMC Physiol, 2011;11:1.
86. Lin L, Saha PK, Ma X, et al., Ablation of ghrelin receptor reduces adiposity and improves insulin sensitivity during aging by regulating fat metabolism in white and brown adipose tissues, Aging Cell, 2011;10:996–1010.
87. Vestergaard ET, Gormsen LC, Jessen N, et al., Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling, Diabetes, 2008;57:3205–10.
88. Gagnon J, Anini Y, Glucagon stimulates ghrelin secretion through the activation of MAPK and EPAC and potentiates the effect of norepinephrine, Endocrinology, 2013;154:666–74.
89. Ikezaki A, Hosoda H, Ito K, et al., Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents, Diabetes, 2002;51:3408–11.
90. Williams J, Mobarhan S, A critical interaction: leptin and ghrelin, Nutr Rev, 2003;61:391–3.
91. Konturek SJ, Pepera J, Zabielski K, et al., Brain-gut axis in pancreatic secretion and appetite control, J Physiol Pharmacol, 2003;54:293–317.
92. Kalra SP, Ueno N, Kalra PS, Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action, J Nutr, 2005;135:1331–5. Review.
93. Engstrom BE, Burman P, Holdstock C, Karlsson FA, Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients, J Clin Endocrinol Metab, 2003;88:5193–8.
94. Iniguez G, Salazar T, Roman R, et al., Effects of the IGF-I/ IGFBP-3 complex on GH and ghrelin nocturnal concentrations in low birth weight children, Clin Endocrinal, 2006;65:687–92.
95. Silva AP, Bethmann K, Raulf F, Schmid HA, Regulation of ghrelin secretion by somatostatin analogs in rats, Eur J Endocrinol, 2005;152:887–94.
96. Paulo RC, Brundage R, Cosma M, et al., Estrogen elevates the peak overnight production rate of acylated ghrelin, J Clin Endocrinol Metab, 2008;93:4440–7.
97. Kellokoski E, Poykko SM, Karjalainen AH, et al., Estrogen replacement therapy increases plasma ghrelin levels, J Clin Endocrinol Metab, 2005;90:2954–63.
98. Chu MC, Cosper P, Nakhuda GS, Lobo RA, A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome, Fertil Steril, 2006;86:1669–75.
99. Matsubara M, Sakata I, Wada R, et al., Estrogen modulates ghrelin expression in the female rat stomach, Pept, 2004;25:289–97.
100. Sugino T, Yamaura J, Yamagishi M, et al., Involvement of cholinergic neurons in the regulation of the ghrelin secretory response to feeding in sheep, Biochem Biophys Res Commun, 2003;304:308–12.
101. Broglio F, Gottero C, Van Koetsveld P, et al., Acetylcholine regulates ghrelin secretion in humans, J Clin Endocrinol Metab, 2004;89:2429–33.
102. Hosoda H, Kangawa K, The autonomic nervous system regulates gastric ghrelin secretion in rats, Regul Pept, 2007;146:12–8.
103. Lainscak M, von Haehling S, Doehner W, Anker SD, The obesity paradox in chronic disease: facts and numbers, J Cachexia Sarcopenia Muscle, 2012;3:1–4.
104. von Haehling S, Morley JE, Anker SD, From muscle wasting to sarcopenia and myopenia: update 2012, J Cachexia Sarcopenia Muscle, 2012;3:213–7.
105. Anker MS, von Haehling S, Springer J, et al., Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology, Int J Cardiol, 2013;162:73–6.
106. Nagaya N, Moriya J, Yasumura Y, et al., Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure, Circulation, 2004;110:3674–9.
107. Nagaya N, Itoh T, Murakami S, et al., Treatment of cachexia with ghrelin in patients with COPD, Chest, 2005;128:1187–93.
108. Miki K, Maekura R, Nagaya N, et al., treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial, PLoS One, 2012;7:e35708.
109. Takiguchi S, Murakami K, Yanagimoto Y, et al., Clinical application of ghrelin in the field of surgery. Surg Today, 2015;45(7):801-807
110. Koch L, Growth hormone in health and disease: Novel ghrelin mimetic is safe and effective as a GH stimulation test, Nat Rev Endocrinol, 2013;9:315.
111. Currow DC, Abernethy AP, Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome, Future Oncol, 2014;10:789–802.
112. Van der Ploeg L, Laken H, Sharma S, et al., Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131, Life Sci, 2014;109:20–9.
113. Álvarez-Castro P, Pena L, Cordido F, Ghrelin in obesity, physiological and pharmacological considerations, Mini Rev Med Chem, 2013;13:541–52.
114. Asakawa A, Inui A, Kaga T, et al., Antagonism of ghrelin receptor reduces food intake and body weight gain in mice, Gut, 2003;52:947–52.
115. Petersen PS, Woldbye DP, Madsen AN, et al., In vivo characterization of high Basal signaling from the ghrelin receptor, Endocrinology, 2009;150:4920–30.
116. Costantini VJ, Vicentini E, Sabbatini FM, et al., GSK1614343, a novel ghrelin receptor antagonist, produces an unexpected increase of food intake and body weight in rodents and dogs, Neuroendocrinology, 2011;94:158–68.
117. Halem HA, Taylor JE, Dong JZ, et al., A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelininduced growth hormone secretion but induces increased body weight gain, Neuroendocrinology, 2005;81:339–49.
118. Holst B, Lang M, Brandt E, et al., Ghrelin receptor inverse agonists: identification of an active peptide core and its interaction epitopes on the receptor, Mol Pharmacol, 2006;70:936–46.
119. Delporte C, Recent advances in potential clinical application of ghrelin in obesity, J Obes, 2012;2012:535624.

Further Resources

Share this Article
Related Content In Obesity
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72